Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2025; 17(9): 109691
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109691
Published online Sep 27, 2025. doi: 10.4254/wjh.v17.i9.109691
Noninvasive prediction of clinically significant portal hypertension in metabolic dysfunction-associated steatotic liver disease compared to other chronic liver diseases
Muaaz Masood, Division of Gastroenterology and Hepatology, Department of Medicine, Center for Digestive Health, Virginia Mason Franciscan Health, Seattle, WA 98101, United States
Ragesh Babu Thandassery, Division of Gastroenterology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States
Ragesh Babu Thandassery, Division of Gastroenterology, Department of Internal Medicine, Central Arkansas Veterans Healthcare System, Little Rock, AR 72202, United States
Author contributions: Masood M was responsible for manuscript writing; Thandassery RB was responsible for concept, manuscript revision, final approval of manuscript; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ragesh Babu Thandassery, DM, MD, Associate Professor, Division of Gastroenterology, Department of Internal Medicine, University of Arkansas for Medical Sci
Received: May 18, 2025
Revised: June 10, 2025
Accepted: September 9, 2025
Published online: September 27, 2025
Processing time: 130 Days and 13.4 Hours
Revised: June 10, 2025
Accepted: September 9, 2025
Published online: September 27, 2025
Processing time: 130 Days and 13.4 Hours
Core Tip
Core Tip: The management of chronic liver disease has increasingly become noninvasive. The Baveno VII consensus recommends a noninvasive strategy to diagnose compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH). However, the diagnostic accuracy of the Baveno criteria for predicting CSPH among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is not well-established. This is pertinent as MASLD has become the leading cause of cACLD in the United States. In this mini-review, we outline the diagnostic performance of the Baveno criteria and other noninvasive scores for predicting CSPH in patients with MASLD and non-MASLD related cACLD.